Advertisement
Letter to the Editor| Volume 82, ISSUE 2, e1-e4, February 2021

Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: A cross-sectional study

  • Author Footnotes
    1 These authors equally contributed to this manuscript.
    Dominique Salmon-Ceron
    Correspondence
    Corresponding author at: Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France.
    Footnotes
    1 These authors equally contributed to this manuscript.
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France

    University of Paris, Paris, France
    Search for articles by this author
  • Author Footnotes
    1 These authors equally contributed to this manuscript.
    Dorsaf Slama
    Footnotes
    1 These authors equally contributed to this manuscript.
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Thomas De Broucker
    Affiliations
    Neurology Department, Delafontaine Hospital, Saint Denis, France
    Search for articles by this author
  • Marina Karmochkine
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Juliette Pavie
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Emmanuel Sorbets
    Affiliations
    Cardiologie Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), 75004 Paris, France

    University of Paris, Paris, France
    Search for articles by this author
  • Nicolas Etienne
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France

    University of Paris, Paris, France
    Search for articles by this author
  • Dominique Batisse
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Gabriela Spiridon
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Valérie Le Baut
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Jean-François Meritet
    Affiliations
    Virology Department, Cochin Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris, France

    University of Paris, Paris, France
    Search for articles by this author
  • Eric Pichard
    Affiliations
    Infectious Disease Department, Hotel Dieu Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris Centre Hôtel-Dieu, 1 Place du Parvis de Notre-Dame, 75004 Paris, France
    Search for articles by this author
  • Florence Canouï-Poitrine
    Affiliations
    INSERM U955, IMRB-CEpiA team, University Paris-Est Créteil, F-94000 Créteil, France

    Clinical Research Unit and Department of Public Health, Henri-Mondor Hospital, University Paris-Est, Assistance Publique Hôpitaux de Paris, F-94000 Créteil, France
    Search for articles by this author
  • on behalf of theAPHP COVID-19 research collaboration
  • Author Footnotes
    1 These authors equally contributed to this manuscript.
Published:December 04, 2020DOI:https://doi.org/10.1016/j.jinf.2020.12.002
      Dear Editor,
      Although most majority of COVID-19 cases are mild as shown in a recent issue of this journal,
      • Chen J.
      • Qi T.
      • Liu L.
      • Ling Y.
      • Qian Z.
      • Li T.
      • et al.
      Clinical progression of patients with COVID-19 in Shanghai, China.
      some patients with initial mild to moderate forms of COVID-19, complain of persistent or resurgent symptoms.
      • Carfì A.
      • Bernabei R.
      • Landi F.
      • Carfì A.
      • et al.
      Gemelli Against COVID-19 Post-Acute Care Study Group
      Persistent symptoms in patients after acute COVID-19.
      Our aim was to describe the clinical, biological and imaging profile of such patients in order to suggest a classification of the symptoms and raise hypotheses about their pathophysiology.
      We established in May 2020, in COCHIN HOTEL DIEU Hospital of Paris, an out-patient clinic for adult patients with persistent and/or recurrent symptoms after a confirmed COVID-19 and performed a cross-sectional monocenter survey on consecutive patients presenting:
      • Chen J.
      • Qi T.
      • Liu L.
      • Ling Y.
      • Qian Z.
      • Li T.
      • et al.
      Clinical progression of patients with COVID-19 in Shanghai, China.
      an initial symptomatic COVID-19 infection virologically confirmed by either a positive SARS-CoV-2 RNA RT-PCR or positive SARS-CoV-2 serology,
      • Carfì A.
      • Bernabei R.
      • Landi F.
      • Carfì A.
      • et al.
      Gemelli Against COVID-19 Post-Acute Care Study Group
      Persistent symptoms in patients after acute COVID-19.
      who developed prolonged COVID symptoms defined as persistent symptoms (> 2 months after the first day of the initial episode) or resurgent symptoms (at least 3 weeks after the 1st episode). The presence of another obvious cause of symptoms was an exclusion criteria.
      Clinical characteristics (previous history, COVID symptoms, physical examination) were collected on a structured questionnaire. A SARS-COV-2 serology was routinely requested. SARS-COV-2 RT-PCR assay on nasopharyngeal swabs and other bioassays were requested based on symptoms. Ethics approval was granted by the local Institutional Review Board of Henri-Mondor Hospital (00011558, Approval number 2020-088). All patients included provided an informed consent. Characteristics of the patients were described by n (%) for categorical data and mean (standard deviation SD) or median (inter-quartile range IQR) for continuous data as appropriate.

      Results

      Among 70 consecutive patients with a documented SARS-CoV-2 infection, median age was 45 (range 23–75), 78.6% were female.
      During the initial episode of COVID-19, the most frequent symptoms were fever, anosmia, headaches and asthenia. Six (8.6%) patients were hospitalized and 2 required oxygen support (Table 1).
      Table 1Demographic characteristics of the 70 patients presenting with persistent and/or re merging late symptoms of COVID after a documented SARS COV 2 infection.
      CharacteristicsAvailable dataAll patients
      Clinical characteristics
      Age, years7045 [36–51]
      Male, No. (%)7015 (21.4)
      Female, No. (%)7055 (78.6)
      Profession
      Healthcare worker, No. (%)6919 (27.5)
      Other, No. (%)6950 (72.5)
      BMI, kg/m²5323.0 [21.1–27.2]
      Allergy6934 (49.3)
      Respiratory allergy, No. (%)6212 (19.4)
      Asthma, No. (%)623 (3.2)
      Medicinal allergy6210 (14.5)
      Other allergy, No622 (2.9)
      Autoimmune disease, No. (%)709 (12.9)
      Personal705 (7.1)
      Familial704 (5.7)
      Anxiety or psychiatric history703 (4.3)
      Smoking, No. (%)662 (3.0)
      Sport practicing, No. (%)5125 (49.0)
      Virologic confirmation of the 1st SARS COV 2 infection
      Positive SARS-CoV-2 RT-PCR positive in rhino pharyngeal swabs4727 (57.4)
      Positive SARS-CoV-2 IgG positive antibodies6964 (92.3)
      Positive SARS-CoV-2 RT-PCR and serology27
      Only a positive SARS-CoV-2 RT-PCR6
      Only a positive SARS-CoV-2 serology37
      Values are median [inter-quartile range] or number (percentage %). BMI: Body Mass Index; COVID-19: Coronavirus Disease 2019; No.: number.
      A symptom-free interval was noted between the first episode and the following episodes in 32/65 cases with a mean interval of 25 days (SD=20). During the prolonged phase, 54.3% patients had symptoms that persisted from the 1st episode, 50% that disappeared and reappeared and 75.7% presented new symptoms that were absent during the 1st episode appeared.
      Characteristics of late symptoms could be classified in 7 main categories (Fig. 1):
      • ­
        Major fatigue or exhaustion for 51 patients (72.9%)
      • ­
        Neurological symptoms, in 54 (77.1%). Those were divided into neuro-cognitive disorders (such as memory, mood or attention disorders), headaches, sensory disturbances (such as balance disorders, tingling, burning sensations and neurogenic pains), or others (swallowing or speech disorders, thermoregulation disorders).
      • ­
        Cardiothoracic symptoms in 50 patients (71.4%): chest pain and tightness, palpitations, cough, dyspnea.
      • ­
        Muscular or/and articular pains for 20 (25.7%).
      • ­
        ENT symptoms: persistent or recurrent anosmia, hyposmia and/or dysgeusia for 21 (30%).
      • ­
        Gastro-intestinal symptoms for 17 (24.3%): diarrhea, nausea/vomiting, epigastric or abdominal pain.
      • ­
        Skin and vascular symptoms in 10 (14.4%).
      Fig. 1
      Fig. 1Distribution of the symptoms of the acute COVID-19 phase versus those of the prolonged -COVID phase in 70 patients presenting with persistent and/or remerging late symptoms of COVID after a confirmed SARS-CoV-2 infection. Legend of the figure: 1. Sensory disturbances include balance disorders, tingling, burning sensations and neurogenic pains. 2. Mucco cutaneo signs include acrocyanosis, rash, flash face, eczema, tongue swelling, pruritus, vascular inflammation, spontaneous ecchymosis. 3. Other cardiological signs include sudden malaise, desaturation. 4. Cognitive psycho disorders include memory, humor or attention disturbances and disorientation. 5. Other neurological signs include or swallowing disorders, thermal dysregulation and speech.
      Other symptoms included odynophagia, low-grade fever, rhinorrhea, conjunctivitis suppress. The majority of the patients (n = 63, 90%) had more than three categories of symptoms. The course of symptoms was intermittent in 42.9% of the cases, alternating symptoms-free intervals of a few days or hours with sudden relapses, often worsening after physical or intellectual exercise.
      During the prolonged COVID-19 phase, the SARS-CoV-2 RT-PCR was still positive in rhino pharyngeal swabs in 11/43 patients and remained positive more than 3 months for 3 subjects (Supplementary Fig. S1). SARS-CoV-2 serology was positive in most of the cases (n = 64/69, 92.8%).
      Inflammatory proteins (C reactive protein, ferritin, IL-6 levels) were in the normal range or slightly elevated in 10% of the patients. Autoimmune antibodies were absent in 90% patients (data not shown). Cardiac echography and/or MRI, led to the diagnosis of pericarditis and/or myopericarditis in 9 cases. Cerebral CT scan and/or MRI were normal, except in 4 cases. An inflammation of olfactive bulbs was occasionally found in case of persistent or recurrent anosmia.

      Discussion

      It was striking that these patients had essentially made a benign form of COVID-19 and consisted mainly of young women. The phenotype was dominated by a major fatigue, associated with neurological and cardiovascular symptoms. If some cases may have been related to the involvement of an organ (pericarditis, myocarditis), some symptom groupings in a same patient were suggestive of an autonomic dysfunction. Another striking finding was that the RT-PCR was occasionally detected in rhino pharyngeal swabs during the prolonged episodes although no patient was immunosuppressed and the majority had developed antibodies against SARS-CoV-2. Unfortunately we were not able to perform viral culture (supplementary Fig. S1).
      The pathophysiology of the persistence of symptoms is currently unknown and probably non univocal. Those observations made us raise several hypotheses.
      The first one is a viral persistence in the host. The virus could continue to replicate in usual sites, as shown in our study and a few previous series.
      • Kang H.
      • Wang Y.
      • Tong Z.
      • Liu X.
      Retest positive for SARS-CoV-2 RNA of “Recovered” patients with COVID-19: persistence, sampling issues, or re-infection?.
      ,
      • Goussef M.
      • Penot P.
      • Gallay L.
      • Batisse D.
      • Bouiller K.
      • Collarino R.
      • et al.
      Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound?.
      It might also have spread elsewhere, via neurological or vascular invasion, in cells reported to express ACE2 receptors such as endothelial cells.
      • Hamming I.
      • Timens W.
      • Bulthuis M.
      • Lely A.
      • Navis G.
      • van Goor H
      Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.
      A second hypothesis is that of a reinfection. Although a rare event, several cases evidenced by a phylogenetically distinct strain of SARS COV-2, have now been demonstrated.

      To K.K., Hung I.F., Ip J.D., Chu A.W., Chan W.M., Tam A.R., Fong C.H., et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis.;ciaa1275. doi:10.1093/cid/ciaa1275.

      Van Elslande J., Vermeersch P., Vandervoort K., Wawina-Bokalanga K., Vanmechelen B., Wollants E., et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain, Clin Infect Dis, ciaa1330, https://doi.org/10.1093/cid/ciaa1330.

      Tillett R., Sevinsky J., Hartley P., Kerwin H., Crawford N., Gorzalski A., et al. Genomic evidence for a case of reinfection with SARS-CoV-2 (2020). Available at SSRN: https://ssrn.com/abstract=3680955 or http://dx.doi.org/10.2139/ssrn.3680955.

      These reinfections have been shown to occur several months after the 1st episode. Knowing that our population consisted of 27% of health care workers, the hypothesis of a reinfection cannot be excluded. However, the difference in clinical profile between the first infection and the prolonged symptoms does not favor of this hypothesis.
      A third hypothesis could be that of an inadequate immune response leading to an auto inflammatory chronic condition in genetically predisposed individual.
      A last hypothesis is that of a condition similar to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). After SARS epidemic in Hong Kong, a follow-up study of 233 patients infected with SARS showed that 27% met the diagnostic criteria for ME/CSF.
      • Lam M.H.
      • Wing Y.K.
      • Yu M.W.
      • Leung C.M.
      • Ma R.C.
      • Kong A.P.
      • et al.
      Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up.
      A subset of patients with prolonged COVID-19 symptoms have symptoms that overlap with ME/CFS.
      Finally, we cannot exclude at this stage the possibility of a post-traumatic stress induced by the COVID-19 pandemic and/or exacerbated by these symptoms themselves.
      One strength of this study it that it focused on patients tested positive for SARS-COV-2 infection, in order to reduce the risk of attributing to COVID 19 symptoms that could be of psycho somatic origin. All our patients filled the same questionnaire and were explored similarly in case of neurological symptoms with a cerebral CT scan and/or MRI and a neurologist advice, and in case cardiothoracic symptoms with an echography and/or a cardiac MRI if needed.
      The limitations are linked to its small sample. Our description could be possibly the tip of the iceberg, only the most affected patients being inclined to visit the clinic. Moreover, our design did not allow us to determine the prevalence of prolonged symptoms. A few recent data establish that more than 20% of patients will present with prolonged symptoms at least for three months among which the fatigue is the predominant symptom although none of them has described precisely the profile of clinical symptoms.
      • Carfì A.
      • Bernabei R.
      • Landi F.
      • Carfì A.
      • et al.
      Gemelli Against COVID-19 Post-Acute Care Study Group
      Persistent symptoms in patients after acute COVID-19.
      ,
      • Tenforde M.W.
      • Kim S.S.
      • Lindsell C.J.
      • Billig Rose E.
      • Shapiro N.I.
      • Files D.C.
      • et al.
      Duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020.
      In conclusion, although prolonged manifestations of COVID-19 are mostly subjective, the repetition of similar neurological and cardiothoracic complaints and the fact that we observed objective cases of myopericarditis suggests that there is a real prolonged COVID-19 entity. We believe that is crucial to promptly report our results to the scientific community as these patients have an urgent need to be taken into account and supported. While waiting to find a virological, immune or inflammatory and/or genetic signature that could explain the symptoms, it is difficult to recommend a treatment.
      Standardized and multidisciplinary investigations and a cohort follow-up are urgently needed in order to precisely assess the prevalence of such symptoms after COVID-19, better understand their pathophysiology and natural evolution and evaluate therapeutic approaches.

      Declaration of Competing Interest

      All the authors have read and agreed with the paper's content. No authors have financial or personal conflicts. Neither the work nor any part of its essential substance, tables or figures have been or will be published or submitted to another scientific journal or are being considered for publication elsewhere.

      Acknowledgments

      The authors would like to thank Mrs Yannie CUVILLIER for technical assistance. We thank all patients who participated in the study. We thank Nicolas DUMESGES for linguistic revision.

      Funding

      This study was not sponsored by any external financial support

      Appendix. Supplementary materials

      References

        • Chen J.
        • Qi T.
        • Liu L.
        • Ling Y.
        • Qian Z.
        • Li T.
        • et al.
        Clinical progression of patients with COVID-19 in Shanghai, China.
        J Infect. 2020; 80 (Epub 2020 Mar 19PMID: 32171869): e1-e6https://doi.org/10.1016/j.jinf.2020.03.004
        • Carfì A.
        • Bernabei R.
        • Landi F.
        • Carfì A.
        • et al.
        • Gemelli Against COVID-19 Post-Acute Care Study Group
        Persistent symptoms in patients after acute COVID-19.
        JAMA. 2020; 324 (PMID: 32644129): 603-605https://doi.org/10.1001/jama.2020.12603
        • Kang H.
        • Wang Y.
        • Tong Z.
        • Liu X.
        Retest positive for SARS-CoV-2 RNA of “Recovered” patients with COVID-19: persistence, sampling issues, or re-infection?.
        JMV. 2020; https://doi.org/10.1002/jmv.26114
        • Goussef M.
        • Penot P.
        • Gallay L.
        • Batisse D.
        • Bouiller K.
        • Collarino R.
        • et al.
        Clinical recurrences of COVID-19 symptoms after recovery: viral relapse, reinfection or inflammatory rebound?.
        J Infect. 2020; (S0163-4453(20)30454-0)
        • Hamming I.
        • Timens W.
        • Bulthuis M.
        • Lely A.
        • Navis G.
        • van Goor H
        Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.
        J Pathol. 2004; 203: 631-637
      1. To K.K., Hung I.F., Ip J.D., Chu A.W., Chan W.M., Tam A.R., Fong C.H., et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis.;ciaa1275. doi:10.1093/cid/ciaa1275.

      2. Van Elslande J., Vermeersch P., Vandervoort K., Wawina-Bokalanga K., Vanmechelen B., Wollants E., et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain, Clin Infect Dis, ciaa1330, https://doi.org/10.1093/cid/ciaa1330.

      3. Tillett R., Sevinsky J., Hartley P., Kerwin H., Crawford N., Gorzalski A., et al. Genomic evidence for a case of reinfection with SARS-CoV-2 (2020). Available at SSRN: https://ssrn.com/abstract=3680955 or http://dx.doi.org/10.2139/ssrn.3680955.

        • Lam M.H.
        • Wing Y.K.
        • Yu M.W.
        • Leung C.M.
        • Ma R.C.
        • Kong A.P.
        • et al.
        Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up.
        Arch Intern Med. 2009; 169 (https://doi.org/): 2142-2147https://doi.org/10.1001/archinternmed.2009.384
        • Tenforde M.W.
        • Kim S.S.
        • Lindsell C.J.
        • Billig Rose E.
        • Shapiro N.I.
        • Files D.C.
        • et al.
        Duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network – United States, March–June 2020.
        MMWR Morb Mortal Wkly Rep. 2020; 69 (PMID: 32730238; PMCID: PMC7392393): 993-998https://doi.org/10.15585/mmwr.mm6930e1